Keebler Health Secures $16M Series A Financing

Keebler Health announced a $16 million Series A round led by Flare Capital Partners, with participation from Sands Capital, Tau Ventures, Freestyle Capital, Hustle Fund, and several other investors. The financing brings Keebler's total capital to $23 million since its 2023 founding. Keebler builds an LLM-native risk adjustment platform that ingests unstructured clinical notes, imaging reports, and discharge summaries to surface missed HCC opportunities and deliver clinician-facing insights at the point of care.

The platform is architected around large language model primitives rather than retrofitted rule-based NLP. Keebler founders include Isaac Park, Andrew Stickney, and Kevin Hill, PhD, with Terrell Bacchus, MD as founding Chief Medical Officer. Key technical capabilities described by the company and investors include:

• •Processing high-volume unstructured clinical documentation to identify condition mentions and temporal context
• •Generating accurate HCC coding suggestions for both retrospective chart review and concurrent workflows
• •Delivering actionable, clinician-oriented prompts at the point of care to minimize workflow disruption
• •Supporting downstream use cases like population health analytics, compliance, and RADV audit readiness

The company emphasizes end-to-end productization rather than research prototypes: models are optimized for clinical precision, audit defensibility, and deployment in live EHR environments. The financing will fund commercial expansion, hiring of engineering and clinical staff, and scaling of infrastructure to meet the throughput and security needs of value-based care customers.

Risk adjustment is a structural problem in value-based care because much clinically meaningful information lives outside coded fields. Studies show chronic conditions are frequently under-captured across EHR sources, producing systematic gaps in risk capture and reimbursement accuracy. Keebler is one of several startups addressing this gap; competitors and adjacent players include Navina and other clinical-intelligence vendors that combine chart review, analytics, and ML.

Keebler's claim to differentiation is that it was built from the ground up as an LLM-native service, which can simplify extraction of nuanced clinical facts like temporality, certainty, and attribution. That positioning aligns with a broader industry trend toward AI-native healthcare platforms that prioritize model explainability, audit logs, and integration with compliance workflows. The presence of sector-focused investors like Flare Capital and Sands Capital signals continued VC appetite for applied healthcare AI that targets near-term revenue capture and regulatory risk reduction rather than pure research play.

For data scientists and ML engineers working in healthcare, Keebler's raise highlights two practical takeaways. First, the market values end-to-end solutions that include clinical validation and operational integration, not just model accuracy metrics. Second, product roadmaps in this space must balance precision with auditability and traceability because payers and regulators will demand defensible outputs for reimbursement and RADV audits.

Track early customer deployments and public benchmarks or validation studies that quantify sensitivity and specificity for HCC detection. Also watch whether Keebler publishes technical details about model fine-tuning, prompt engineering, or human-in-the-loop workflows that underpin audit defensibility.

The Series A positions Keebler to scale commercialization of an LLM-native risk adjustment product at a time when accurate capture of unstructured clinical data has direct financial and regulatory consequences for value-based care organizations.